Journal profile · Respiratory System
Sarcoidosis vasculitis and diffuse lung diseases
ISSN 1124-0490 · eISSN 2532-179X · Mattioli 1885 S.p.A. · ITALY · Tri-annual · Founded 1996
Sarcoidosis vasculitis and diffuse lung diseases: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.61; fully open access; median 82 days to acceptance (97 articles, last 24 months); 60 articles a year; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Sarcoidosis vasculitis and diffuse lung diseases is published by Mattioli 1885 S.p.A. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Sarcoidosis and Beryllium Toxicity Research and Legal and Regulatory Analysis, together about 46.1% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Sarcoidosis, Vasculitis and Diffuse Lung Disease is a quarterly journal founded in 1984 by G. Rizzato. It is the oldest and most prestigious Italian journal in such field.This journal is regularly listed in bibliographic services, including Scopus, Current Contents/ Clinical Medicine, the Science Citation Index (Web of Science), Sci Search, Research Alert, Index Medicus/Medline (PubMed, PubMedCentral), EMBASE/Excerpta Medica (Priority Journals). The Journal publishes 4 regular issues for year: N. 1 (March issue), N. 2 (June issue), N. 3 (September issue), N. 4 (December issue).
From the journal's Aims & Scope
Research area (LetPub): Respiratory System
Editorial board by country: none in mainland China; most named United States 2, United Kingdom 2, Italy 2 (6 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisMedicine15.4%
- Sarcoidosis and Beryllium Toxicity ResearchMedicine15.4%
- Legal and Regulatory AnalysisSocial Sciences15.4%
- Linguistic, Cultural, and Literary StudiesSocial Sciences15.4%
- Military Technology and StrategiesEngineering15.4%
- Chronic Obstructive Pulmonary Disease (COPD) ResearchMedicine7.7%
- Pulmonary Hypertension Research and TreatmentsMedicine7.7%
- Amyloidosis: Diagnosis, Treatment, OutcomesBiochemistry, Genetics and Molecular Biology7.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCurrent ContentsPublisher website
Other: Portico, Research Alert, SJR (Scimago Journal & Country Rank)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.61LetPub ·
- Impact factor (publisher) 2025
- 1.8Publisher website ·
- CiteScore 2026-06
- 2LetPub ·
- CiteScore (publisher) 2025
- 2Publisher website ·
- SJR 2026-06
- 0.5LetPub ·
- SJR (publisher)
- 1.8Publisher website ·
- SNIP 2026-06
- 0.73LetPub ·
- SNIP (publisher)
- 0.5Publisher website ·
- h-index
- 51LetPub ·
- h-index
- 1OpenAlex ·
- i10-index
- 1OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Self-citation rate
- 22.2%LetPub ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year
- 60LetPub ·
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
82 daysMedian, submission to acceptance · P25–P75 53 days – 124 days
- Acceptance to online
- median 139 days (97 articles)
- Submission to online
- median 238 days
- Sample
- 97 articles with submission and acceptance dates (133 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteConflicts of interest, License & copyright, Peer review
- Conflicts of interest Policies on Conflict of Interest, Human and Animal rights, and Informed Consent
Competing interests Sarcoidosis Vasculitis and Diffuse Lung Diseases requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests’ section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read “The authors have de…
Source ↗Publisher website ·- License & copyright PROPERTY AND COPYRIGHT
Associazione Italiana Pneumologi Ospedalieri – Italian Thoracic Society (AIPO-ITS/ETS) Via Antonio da Recanate, 2 - 20124 Milano Tel. +39 02 36590367, Fax + 39 02 66790405 www.aiponet.it - E-mail: [email protected] Società Italiana Di Pneumologia / Italian Respiratory Society (SIP/IRS ) Via San Gregorio, 12, 20124 – Milano – Italy Tel. +39 0249453331, Fax + 39 0287036090 www.sipirs.it, E-mail: [em…
Source ↗Publisher website ·- Peer review Peer Review Process
The practice of peer review is to ensure that manuscript is published. It is a process at the heart of good scholarly publishing and is carried out on all reputable journals. Our referees play a vital role in maintaining the high standards of Sarcoidosis, Vasculitis and Diffuse Lung Diseases and manuscripts are peer reviewed following the procedure outlined below. Special Issues have different pee…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Mattioli 1885 S.p.A.
- Country or region
- ITALY
- Language
- English
- Frequency
- Tri-annual
- Founded
- 1996
- ISSN
- 1124-0490
- Electronic ISSN
- 2532-179X
- Society / sponsor
- World Association of Sarcoidosis and other Granolumatous Disorders
- Latest issue on the website
- Volume 43, Issue 2 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Sarcoidosis vasculitis and diffuse lung diseases
What CAS zone is Sarcoidosis vasculitis and diffuse lung diseases in?
In the 2025 upgraded edition of the CAS Journal Ranking, Sarcoidosis vasculitis and diffuse lung diseases is in Zone 4 of Medicine, and in Zone 4 of the minor category Respiratory System. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Sarcoidosis vasculitis and diffuse lung diseases?
The latest impact factor listed by LetPub is 1.61; CiteScore 2, h-index 1.
How long does peer review take at Sarcoidosis vasculitis and diffuse lung diseases?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 82 days (interquartile range 53–124 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Sarcoidosis vasculitis and diffuse lung diseases based?
Of the 6 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (2), United Kingdom (2) and Italy (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Sarcoidosis vasculitis and diffuse lung diseases?
According to LetPub and DOAJ records, Sarcoidosis vasculitis and diffuse lung diseases is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase and Current Contents; that list has not been checked against each database.
Is Sarcoidosis vasculitis and diffuse lung diseases open access, and what is the APC?
Sarcoidosis vasculitis and diffuse lung diseases is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .